Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Department of Internal Medicine, Clinical Emergency Hospital of Bucharest, 14461 Bucharest, Romania.
Medicina (Kaunas). 2021 Nov 23;57(12):1288. doi: 10.3390/medicina57121288.
Polypharmacy is associated with drug-drug or food-drug interactions that may pose treatment difficulties. The objective of the study was to investigate the use of polypharmacy in hypertensive patients hospitalized in the Internal Medicine Clinic of a European referral hospital. We conducted a retrospective chart review study on patients identified by a database search of discharge diagnoses to assess the use of polypharmacy and identify potential drug-drug and food-drug interactions. In total, 166 hypertensive patients (68.46 ± 12.70 years, range 42-94 years) were compared to 83 normotensive subjects (67.82 ± 14.47 years, range 22-94 years) who were hospitalized in the clinic during the same period. Polypharmacy was more common in hypertensive versus normotensive subjects ( = 0.007). There were no differences in terms of age, as well as major (0.44 ± 0.77 versus 0.37 ± 0.73 interactions/patient, = 0.52) and minor (1.25 ± 1.50 versus 1.08 ± 1.84 interactions/patient, = 0.46) drug-drug interactions between patients with and without hypertension. The mean number of drug-drug interactions (6.55 ± 5.82 versus 4.93 ± 5.59 interactions/patient, = 0.03), moderate drug-drug interactions (4.94 ± 4.75 versus 3.54 ± 4.17, = 0.02) and food-drug interactions (2.64 ± 1.29 versus 2.02 ± 1.73, = 0.00) was higher in patients with hypertension versus their counterparts. The present study reinforces that polypharmacy is a serious concern in hypertensive patients, as reflected by the high number of potentially harmful drug-drug or food-drug interactions. We recorded higher numbers of comorbidities, prescribed drugs, and moderate drug-drug/food-drug interactions in hypertensive versus normotensive patients. A strategy to evaluate the number of discharge medications and reduce drug-drug interactions is essential for the safety of hypertensive patients.
药物治疗方案数量过多与药物-药物或食物-药物相互作用有关，可能会增加治疗难度。本研究的目的是调查在一家欧洲转诊医院的内科诊所住院的高血压患者中药物治疗方案数量过多的情况。我们对通过数据库搜索出院诊断确定的患者进行了回顾性图表审查研究，以评估药物治疗方案数量过多的情况，并确定潜在的药物-药物和食物-药物相互作用。共有 166 名高血压患者（68.46±12.70 岁，范围 42-94 岁）和同期在该诊所住院的 83 名血压正常的患者（67.82±14.47 岁，范围 22-94 岁）进行了比较。与血压正常的患者相比，高血压患者的药物治疗方案数量更多（=0.007）。两组患者在年龄方面没有差异，主要（0.44±0.77 与 0.37±0.73 个相互作用/患者，=0.52）和次要（1.25±1.50 与 1.08±1.84 个相互作用/患者，=0.46）药物-药物相互作用也没有差异。高血压患者的药物-药物相互作用数量（6.55±5.82 与 4.93±5.59 个相互作用/患者，=0.03）、中度药物-药物相互作用（4.94±4.75 与 3.54±4.17，=0.02）和食物-药物相互作用（2.64±1.29 与 2.02±1.73，=0.00）的平均值高于血压正常的患者。本研究再次证实，高血压患者的药物治疗方案数量过多是一个严重的问题，这反映在大量潜在的有害药物-药物或食物-药物相互作用上。与血压正常的患者相比，高血压患者的合并症、开处的药物以及中度药物-药物/食物-药物相互作用更多。评估出院药物数量并减少药物-药物相互作用的策略对于高血压患者的安全至关重要。
